VolitionRX Ltd (NYSE American:VNRX)
| 0.761 Delayed Data As of Sep 25 |  +0.0679 / +9.80%Today’s Change | 0.63 Today|||52-Week Range 2.74 | -68.68% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $54.2M |
Company Description
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
Contact Information
VolitionRX Ltd. 1489 West Warm Springs Road Henderson Nevada 89014 |
Employees
Shareholders
| Other institutional | 6.61% |
| Individual stakeholders | 24.16% |
| Mutual fund holders | 1.65% |
Top Executives
| Cameron John Reynolds | President, Chief Executive Officer & Director |
| Gaetan Michel | Chief Operating Officer |
| Terig Hughes | Chief Financial Officer & Treasurer |
| Jacob Vincent Micallef | Chief Scientific Officer |
| Mark Eccleston | Chief Technology Officer |
